Free tool
FAERS Monitor: Tikosyn
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020931 or its brand name (Tikosyn, Dofetilide). Reports on generic versions are filed under their own applications.
Reports
10,514
Serious
6,255
59% of reports
Hospitalization
3,009
Death reported
812
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- atrial fibrillation1,071
- drug ineffective1,035
- dyspnoea622
- dizziness564
- fatigue536
- death485
- electrocardiogram qt prolonged447
- headache398
- diarrhoea330
- malaise323
- drug interaction298
- nausea296
- asthenia294
- heart rate increased289
- arrhythmia268
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 249 |
| 2005 | 196 |
| 2006 | 156 |
| 2007 | 118 |
| 2008 | 81 |
| 2009 | 100 |
| 2010 | 681 |
| 2011 | 347 |
| 2012 | 487 |
| 2013 | 576 |
| 2014 | 708 |
| 2015 | 829 |
| 2016 | 947 |
| 2017 | 628 |
| 2018 | 650 |
| 2019 | 927 |
| 2020 | 566 |
| 2021 | 460 |
| 2022 | 417 |
| 2023 | 416 |
| 2024 | 455 |
| 2025 | 321 |
| 2026 | 199 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,645 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| electrocardiogram qt prolongedSignal | 447 | 25.2 | 23.0 | 10,237 |
| atrial fibrillationSignal | 1,071 | 22.2 | 21.0 | 21,558 |
| arrhythmiaSignal | 268 | 11.4 | 10.1 | 2,518 |
| heart rate increasedSignal | 289 | 5.8 | 5.2 | 1,159 |
| drug interactionSignal | 298 | 3.8 | 3.4 | 605 |
| dizzinessSignal | 564 | 2.3 | 2.1 | 406 |
| dyspnoeaSignal | 622 | 2.2 | 2.0 | 416 |
| drug ineffective | 1,035 | 1.6 | 1.5 | 229 |
| asthenia | 294 | 1.6 | 1.4 | 60 |
| malaise | 323 | 1.5 | 1.3 | 50 |
| fatigue | 536 | 1.4 | 1.3 | 57 |
| headache | 398 | 1.3 | 1.2 | 23 |
| death | 485 | 1.1 | 1.0 | 7 |
| diarrhoea | 330 | 1.0 | 0.9 | 0 |
| nausea | 296 | 0.7 | 0.7 | 26 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.